Core Viewpoint - Vireo Growth Inc. is expanding its retail presence in Colorado by acquiring 17 dispensaries from PharmaCann Inc., bringing its total to 41 dispensaries in the state, which strengthens its leadership position in the adult-use retail market [1][2]. Group 1: Transaction Details - The total consideration for the acquisition is approximately $49.0 million, payable in subordinate voting shares at closing, along with the assumption of certain liabilities [2]. - The share consideration will be adjusted based on inventory levels and trade payables of the acquired dispensaries, and will be subject to customary resale restrictions under Canadian securities law [2]. - A Management Services Agreement has been established, allowing one of Vireo's subsidiaries to manage the acquired dispensaries until the closing, pending necessary regulatory approvals [2]. Group 2: Strategic Implications - The CEO of Vireo, John Mazarakis, emphasized that this transaction aligns with the company's strategy of growth through accretive mergers and acquisitions, complementing other recent acquisitions in Colorado [3]. - Vireo was founded in 2014 as a pioneering medical cannabis company, focusing on building a disciplined and execution-oriented platform in the industry [3].

Key Takeaways Berkshire's insurance float hit $176B in Q3 2025, backed by strong investments and financial flexibility.MET's New Frontier strategy targets cost cuts, global growth and AI-driven operational efficiency.MET boasts 21% ROE and 2025 EPS growth estimate of 7.2%, topping BRK.B's 7.3% ROE and 5.2% EPS decline.The Federal Reserve, in its latest meeting, cut interest rates for the third time in 2025, and there is a probability of one more next year. Meanwhile, equity markets continue to perform satis ...

World Stock Exchange, whether it's the French one, the Dutch one, the German one are too small. Do you think do you think they'll grow or actually as much they should merge all of them. I mean, there's talk about merging right now, but the French is already with Milano and Wiz with Holland.But the German people have always tried to do something on their side. They they did an acquisition, I remember recently, but it's not on the stock market. But that would be they should just should just merge. ...

CorpGov hosted a fireside chat on Dec. 9 from the floor of the New York Stock Exchange with Jon Feldman, Partner and Business Law Group Head at Goodmans LLP. The in-person interview was joined by Editor-in-Chief John Jannarone and they discussed the current Canadian proxy space, why there have been numerous take-private transactions, and more. Watch the full interview below, or click HERE: About Jon Feldman Jon Feldman is a partner and heads a business law group at Goodmans. His practice focuses on corp ...

The UK’s consolidation wave is primarily rooted in a fiscal regime that has steadily hardened since the introduction of the Energy Profits Levy (EPL) in May 2022. Triggered by the surge in oil and gas prices following the pandemic and start of the war in Ukraine, the levy was initially presented as a temporary windfall tax aimed at capturing extraordinary profits while British households faced soaring energy bills. However, what followed was a series of extensions by both the conservative and labour governm ...

TORONTO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- First Nordic Metals Corp. (TSX-V: FNM, FNSE: FNMC SDB, OTCQX: FNMCF, FRA: HEG0) (“First Nordic” or the “Company”) and Mawson Finland Limited (“Mawson”) (TSX-V: MFL, FRA: PM6) are pleased to announce the successful closing of the previously announced acquisition by First Nordic of all of the issued and outstanding common shares of Mawson (the “Mawson Shares”) by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Transacti ...

US-listed biotech and pharma company share sales are staging a late-year revival, with M&A in the industry boosting valuations and stoking additional demand https://t.co/M7fHJQVbeL ...

Key Takeaways Five biotech stocks are highlighted for 2026 due to late-stage trials or upcoming FDA decisions.MindMed expects multiple phase III data readouts in 2026 for its lead program MM120.Ocugen, Kyverna and Celcuity face key inflection points tied to BLAs or pivotal clinical data.After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements with the Trump administrati ...

MIAMI, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Standard Premium Finance Holdings, Inc. (OTCQX: SPFX) (“Standard Premium”), a leading specialty finance company, today shares its perspective on key trends shaping the insurance premium finance market in 2026 and defines performance objectives aligned with its long-term growth strategy. Standard Premium has expanded its operating footprint to 40 licensed states and more than doubled its available capital through a recently expanded $115 million credit facility, posit ...

Technology dealmakers are just beginning a supercharged period of mergers and acquisitions activity after racking up a record run this year, according to a senior Morgan Stanley banker https://t.co/nt86NnCIgw ...